Furthermore, the dominant role of tau along with the well-reported data that tau correlates with cognitive decline better than Aβ (Nelson et al., 2012) could also explain the failure of a number of Aβ-based AD clinical trials. This evidence concerns the gene MAPT and Alzheimer disease.